Gerald P. Linette, M.D., Ph.D.
- Assistant Professor
- Department of Medicine
- Oncology Division
- Medical Oncology Section
- Oncology Division
- Department of Neurological Surgery
- Department of Medicine
- Clinical interests
- Neuro-oncology
- Melanoma
- Research interests
- Immunologic approaches for the treatment of cancer
- Pathogen-specific CD8 immunity
Research
Human Cancer Immunology
The identification of melanocyte-lineage restricted antigens (such as gp100 and MART1/Melan-A) that are over-expressed in metastatic melanoma serves as the starting point for vaccine strategies to elicit tumor specific effector T cells. Recent data from our laboratory shows that melanoma specific cytotoxic T lymphocytes (CTL) can be isolated from patients that are immunized with gp100 melanoma antigen peptide-pulsed dendritic cells (DC). In a phase I clinical trial, all 12 patients had detectable circulating melanoma-peptide specific CTL after DC vaccination. Our interest is to develop additional clinical trials using DC to hyper-immunize patients with advanced melanoma. Immunological monitoring of patients is essential toward understanding the kinetics and magnitude of melanoma antigen specific CTL after immunization. Full characterization of antigen-specific CTL from immunized patients is viewed as a high priority. Tumor profiling will be done longitudinally to assess mechanisms of resistance and immune evasion. The long term goal is to create effective immunotherapies for patients with advanced melanoma.
Glioma Biomarkers
The standard treatment for human glioblastoma multiforme (grade IV astrocytoma) is surgical resection followed by radiation with concurrent temozolomide followed by adjuvant temozolomide. Despite recent advances with addition of chemotherapy, most patients develop disease progression by 12 months. In a collaborative effort with members of the Neuro-Oncology faculty, my interest is to develop new clinical trials utilizing novel biomarkers to stratify patients into treatment groups evaluating investigational therapies. The long term goal is to employ a biomarker based strategy to select optimal first line treatment for patients with glioblastoma multiforme.
|
Hierarchical clustering of cDNA gene expression data in patients with newly diagnosed stage I-III breast cancer
|
From: Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L
Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips.
J Mol Diagn 2005 Aug;7(3):357-67
Biographical Sketch
Education
| 1976-1980 | BS (Biology), St. Joseph's University, Philadelphia, PA |
| 1984-1990 | MD/PhD (Microbiology), Georgetown University School of Medicine, Washington, DC |
Post-graduate Training
| 1990-1992 | Intern and Resident, Medicine, Barnes Hospital, St. Louis, MO |
| 1992-1995 | Research Fellow, Molecular Oncology, Washington University, St. Louis, MO |
| 1995-1998 | Clinical Fellow, Hematology-Oncology, Massachusetts General Hospital, Boston, MA |
| 2005 | Visiting Scientist, Neuro-Oncology Branch, NIH/NCI/NINDS, Bethesda, MD |
Academic Appointments
| 1980-1984 | Research Specialist in Immunology, Department of Medicine, University of Pennsylvania, Philadelphia, PA |
| 1995-1998 | Clinical and Research Fellow, Department of Medicine, Harvard Medical School, Boston, MA |
| 1998-2001 | Instructor, Department of Medicine, Harvard Medical School, Boston, MA |
| 2001-present | Assistant Professor of Medicine, Washington University School of Medicine, St. Louis, MO |
Industry Experience
| 2002-2004 | Director, Molecular Oncology, Millennium Pharmaceuticals, Inc., Cambridge, MA |
Hospital Service
| 2001-present | Medical Director, Melanoma Service, Siteman Cancer Center |
| 2005-present | Medical Director, Neuro-Oncology Service, Siteman Cancer Center |
| 2006-present | Medical Director, GMP Facility, Siteman Cancer Center |
Board Certification
| 1997 | Diplomate, American Board of Internal Medicine |
| 1999 | Diplomate, American Board of Internal Medicine (Medical Oncology) |
Awards & Honors
| 1988 | Special Commendation for Pre-doctoral Presentation, IV International Conference on AIDS, Stockholm, Sweden |
| 1992 | Post-Graduate Medical Scientist, Washington University School of Medicine |
| 1997 | PhRMA Fellow in Clinical Pharmacology |
| 2000 | NIH/NCI Research Career Development Award |
Editorial Boards
| 2000-present | International Journal of Cancer, reviewer |
| 2000-present | Clinical Cancer Research, reviewer |
| 2001-present | Gene Therapy, reviewer |
| 2002-present | Cancer Investigation, reviewer |
| 2003-present | British Journal of Dermatology, reviewer |
| 2005-present | Clinical and Experimental Dermatology, reviewer |
| 2006-present | PLoS Medicine, reviewer |
| 2007-present | Journal of Nuclear Medicine, reviewer |
Professional Memberships
| 1996 | American Society of Hematology |
| 1997 | American Society of Clinical Oncology |
| 1998 | American Society of Immunologists |
| 1998 | American Society for Cancer Research |
| 2000 | International Society for Cellular Therapy |
| 2007 | Society for Neuro-Oncology |
Major Committee Assignments
| 1996-2001 | MGH Melanoma Disease Center |
| 1998-1999 | DFCI/PCC Gynecologic Oncology Subcommittee on Immunotherapy |
| 1999-2001 | Harvard Cancer Center, Committee on Cancer Immunology |
| 2001-present | Siteman Cancer Center, Melanoma Program |
| 2005-present | Siteman Cancer Center, Neuro-Oncology Program |
| 2006-present | NCCN Central Nervous System Cancers Panel, member |
| 2006-present | Washington University, Human Studies Committee, member |
Updated: April 21, 2008
